Drug
TD 1473 Dose A
TD 1473 Dose A: highest development phase Phase 2/3, developed by Theravance Biopharma. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Theravance Biopharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| TD-1473 Dose A NCT03758443 | Phase 2/3 | Ulcerative Colitis (UC) |
| TD-1473 Dose A NCT03920254 | Phase 2/3 | Ulcerative Colitis (UC) |
| TD-1473 - Dose A NCT03750565 | Phase 1 | Inflammatory Bowel Diseases |
Latest
No recent events.
Follow TD 1473 Dose A on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.